We are proud to offer the world’s largest off-the-shelf collection of compounds for biological screening. Comprising of 3M+ drug-like structures our collection has been proven to be an excellent source of starting points for the development of MedChem targets and analogues for hit expansion. Outstanding diversity of our collection ensures efficient coverage of the entire chemical space of commercially available screening compounds.
The compounds can be easily searched and purchased at enaminestore.com or requested as a cherry-picked set. Our CADD team is at your service to compile pre-profiled or target-focused compound selections via filtering by phys-chem parameters, similarity and substructure searches, ligand-based and structure-based virtual screening, as well as pharmacophore modelling.
Through Enamine’s in-house validated parallel synthesis technology our screening collection is complemented with 150 000 new compounds yearly.
Thanks to the early focus of the company on development of its own inventory of MedChem relevant Building Blocks, the key emphasis of synthesis of new screening compounds is placed on the structural quality, uniqueness, diversity and molecular profile compliant with the modern trends in drug design.
All Screening compounds in our stock are split into Premium, Advanced, HTS and Functional Collections in accordance with their key structural aspects and molecular properties:
- Most extensive
- Most diverse
- Most affordable
- Ultimate novelty (<2-years)
- Structures well-suited for lead discovery and targeted library design
- Valuable pharmacophores present & Rigorous MedChem filters applied
- Outstanding structural quality and uniqueness
- Excellent synthetic tractability
- Prompt and efficient hit-follow-up guaranteed
- Known bioactive compounds referred in open public domain
- Covalent binders available
- Compounds for PROTAC design
- Cherry-picking about 300k pre-dissolved compounds
- Quickest delivery
- Readily available as up to 10uL of 10mM DMSO solutions
Notably, according to the feedback from our most significant customers, the majority of sizable compound selections purchased for screening campaigns are compiled of at least 50% of Enamine compounds.
Get access to > 100 suppliers through Chemspace
Availability, Packaging, Quality Control
The compounds are available in multi-milligram amounts sufficient for fast re-supply (typically 100-300 mg). The samples are mainly stored as dry powders and can be delivered either dry, or as DMSO solutions of preferred concentration and volume, including “assay-ready”, in containers of your choice:
- individual vials, 96-, 384- or 1536-well microplates
- 2D-barcoded tube racks and Echo-qualified source plates
Mostly oily and sticky compounds are stored and shipped as DMSO solutions and are included to “Liquid Stock” to ensure smooth handling.
All Enamine compounds undergo rigorous quality control with LCMS and/or 1H NMR to meet the requirement of 90% purity. Higher quality standards (95%, 97%) are achievable via additional HPLC purification at extra charge. To ensure greater accuracy of the screening results we guarantee fast hit re-supply from the same batch in most cases. Additional purification and enhanced characterization can be offered as an additional service package.
- Overlap of On-demand Ultra-large Combinatorial Spaces with On-the-shelf Drug-like Libraries.
Perebyinis M., Rognan D. Molecular Informatics 2022, e2200163. DOI: 10.1002/minf.202200163
- Identification and validation of potent Mycobacterial proteasome inhibitor from Enamine library.
Tyagi R., Srivastava M., Singh B. et al. J Biomol Struct Dyn. 2021, 1-11. DOI: 10.1080/07391102.2021.1914173
- Evolution of commercially available compounds for HTS.
Volochnyuk D., Ryabukhin S. et al. Drug Discov Today. 2019, 24 (2), 390-402. DOI: 10.1016/j.drudis.2018.10.016
- Development and implementation of a cell-based assay to discover agonists of the nuclear receptor REV-ERBα.
Hering Y., Berthier A., Duez H. et al. J Biol Methods 2018, 5 (3), e94. DOI: 10.14440/jbm.2018.244
- Identification of novel small molecules that inhibit STAT3-dependent transcription and function.
Kolosenko I., Yasmin Yu, Busker S. et al. PLoS One. 2017, 12 (6), e0178844. DOI: 10.1371/journal.pone.0178844